Q-omics provides the consensus-scored SRI profile across patient tissues and cancer cell-line models. SRI expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SRI is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SRI protein abundance shows 26,771 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight CESC, COAD, and PDAC as cancer lineages where SRI shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRI — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRI survival associations across molecular data types. SRI RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRI RNA expression–survival associations across cancer types. High SRI expression shows unfavorable associations in CESC, PAAD, HNSC, KIRP, UVM and STAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for SRI RNA expression.
This table summarizes SRI tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SRI. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRI shows lower tumor expression in COAD and READ and higher tumor expression in HNSC, KIRP, LIHC and STAD. The COAD box plot shows higher SRI RNA expression in normal versus tumor tissue (log2 FC = −1.655, t-test p < 0.001).
This table shows molecular features associated with SRI in patient tissues and cancer cell lines. In patient samples, SRI shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SRI RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
